Phase IIa trial of Vacc-4x given in combination with GM-CSF adjuvant in patients with chronic HIV-1 infection who had complete suppression of HIV-1 by antiretroviral therapy.
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Vacc-4x (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications HIV-1 infections
- Focus Therapeutic Use
- 29 Jan 2018 According to a Bionor media release, Bionor Pharma changed its name to Bionor Holding.
- 05 Nov 2010 New trial record.